Trials / Completed
CompletedNCT00792623
Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).
A Phase III, Open-label, Multi-centre Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM), Given as a Primary Vaccination at 4.5 Months and 6.5 Months Post-transplantation, in Autologous Stem Cell/ Bone Marrow Transplant Recipients Aged 18 Years and Older.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to assess the immunogenicity and safety of varicella vaccination in a population of autologous peripheral stem cell/ bone marrow transplantation recipients who have reached at least four months post-transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VarilrixTM | Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm. |
Timeline
- Start date
- 2003-09-08
- Primary completion
- 2007-09-10
- Completion
- 2007-09-10
- First posted
- 2008-11-18
- Last updated
- 2018-11-08
- Results posted
- 2017-07-06
Locations
3 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00792623. Inclusion in this directory is not an endorsement.